Results 151 to 160 of about 530,731 (290)

Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1. [PDF]

MAbs
Kwon JA, Lee S, Kim J, Yoo BM, Park HJ, Ryu I, Kim J, Eom J, Son YG, Yeom D, Sung B, Yoo M, Seo A, Yoo J, Park JY, Jung J, Ahn J, You WK, Lee SH, Ko MJ.   +19 more
europepmc   +1 more source

Spatial Atlas of Small Cell Lung Carcinoma Reveals Intratumoral Tumor‐State Heterogeneity and an MMP12+ Macrophage Niche

Cancer Science, EarlyView.
Spatial transcriptomic profiling of SCLC revealed marked intratumoral heterogeneity, including coexisting neuroendocrine and non‐neuroendocrine states and spatially heterogeneous hypoxia, and identified an MMP12+ macrophage population enriched at hypoxic and necrotic tumor interfaces.
Naozane Nomura, Naoe Jimbo, Takaaki Nakanishi, Yukinobu Ito, Maki Sakaguchi, Daichi Maeda, Hiroko Ikeda, Tsukasa Ueda, Hayato Koba, Seiji Yano, Isao Matsumoto, Patrick Micke, Takayuki Kodama, Manabu Shigeoka, Yu‐ichiro Koma, Masafumi Horie   +15 more
wiley   +1 more source

Bispecific Antibody-Based Combination Therapies for B-Cell Lymphomas: Current Evidence and Future Perspectives. [PDF]

Int J Cancer
Cheng M, Li W, Liu M, Zou L.
europepmc   +1 more source

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies. [PDF]

Pathophysiology
Tai D, Sandhu N, Dermarderosian A, Mkrtchyan N, Park D, Garg V, Nguyen A, Akhtari M.   +7 more
europepmc   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

bispecific antibody

Citation: 'bispecific antibody' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12951 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source

Cytotoxic activity and safety characterization of IMV-M™, a MUC16 × DR5 bispecific antibody. [PDF]

Antib Ther
Goldmacher VS, Gershteyn IM.
europepmc   +1 more source

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli, Daniele Mannina, Alessandro Corrente, Chiara De Philippis, Ilaria Pansini, Marcello Viscovo, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Stefania Bramanti, Simona Sica   +10 more
wiley   +1 more source

Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. [PDF]

Ann Med Surg (Lond)
Ali H, Hilal H, Gul M, Asad M, Jaber Amin MH.   +4 more
europepmc   +1 more source